TCGA-50-5066-01A-01R-1628-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- OXIDATIVE_PHOSPHORYLATION+0.470
- INFLAMMATORY_RESPONSE+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- PANCREAS_BETA_CELLS+0.320
- COMPLEMENT+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- IL6_JAK_STAT3_SIGNALING+0.280
- KRAS_SIGNALING_UP+0.280
- MYC_TARGETS_V1+0.280
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.520
- MITOTIC_SPINDLE-0.480
- HEDGEHOG_SIGNALING-0.430
- APICAL_JUNCTION-0.270
- G2M_CHECKPOINT-0.250
- ESTROGEN_RESPONSE_EARLY-0.230
- NOTCH_SIGNALING-0.190
- TGF_BETA_SIGNALING-0.180
- UV_RESPONSE_DN-0.180
- ANDROGEN_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.919 |
| 2 | TCGA-64-1676-01A-01R-0946-07 | — | cohortA1 | 0.886 |
| 3 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.873 |
| 4 | TCGA-37-3783-01A-01R-1201-07 | — | cohortSQ1 | 0.858 |
| 5 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.845 |
| 6 | TCGA-35-4123-01A-01R-1107-07 | — | cohortA1 | 0.844 |
| 7 | MDT-AP-2183 | Med | Medulloblastoma | 0.843 |
| 8 | MDT-AP-2299 | Med | Medulloblastoma | 0.835 |
| 9 | AUR-AFR2-TTP1-A-1-1-R-A742-41 | — | C | 0.834 |
| 10 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.470 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |